Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down

 
• By Alaric DeArment
  
Cardiff is pursuing a narrower CRC market for onvansertib as its CEO and CFO stepped down amid the announcement of Phase II results. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D